The DAPT Study: The Dual Antiplatelet Therapy (DAPT) Study
The aim of this study is to conduct a multicenter, international, randomized, double-blind trial to help the global medical community to better assess the effectiveness and safety of 12 versus 30 months of dual antiplatelet therapy in subjects without contraindications following percutaneous coronary intervention (PCI) with either drug-eluting stent (DES) or bare metal stent (BMS) placement for the treatment of coronary artery lesions.
Winthrop-University Hospital - Division of Cardiology is conducting this clinical research trial for participants, greater than 18 years of age and who have undergone percutaneous intervention with stent deployment. All enrolled subjects will be treated according to the standard of practice for the thienopyridine treatment in addition to aspirin for first 12 months after the index procedure. Eligible subjects will be randomized 1:1 at 12 months to receive placebo or thienopyridine treatment for an additional 18 months. Subjects will be followed for an additional 3 months for observational follow-up at the end of the 18 month randomized treatment phase.
To be eligible for this clinical trial, you must: - Be older than 18 years - Must have undergone percutaneous intervention with stent deployment.
Srihari Naidu, MD
Division of Cardiology
For more information please call Research Coordinator at 516-663-8692.